Sarepta shares leap on FDA’s eteplirsen overview delay

stocks of Sarepta Therapeutics rose nearly 27 percent Wednesday after announcing the meals and Drugadministration is delaying its evaluate of a key drug made through the company. The FDA notified Sarepta that “they are persevering with their evaluation and internal

Read More Sarepta shares leap on FDA’s eteplirsen overview delay